Comorbid celiac disease (CD) may affect the course of type 1 diabetes (T1D). We aimed to compare T1D children with and without CD. This study is based on the SWEET (Better control in Pediatric and Adolescent diabeteS:Working to crEate cEnTers of Reference) database. We included 39 425 patients aged ≤18 y. Regression models adjusted for demographics were applied to compare outcomes. CD was present in 1 804 subjects (4.6%). Prevalence of CD differed among regions: 1.9% Asia/Middle East, 4.3% Northern Europe, 5.1% Southern Europe, 5.3% North America/Canada and 6.1% Australia/New Zealand. Girls were diagnosed with CD significantly more often than boys (p< 0.01). Children with CD were younger at diabetes onset (p< 0.001), also when boys and girls were separately analyzed. CD subjects were significantly shorter (p= 0.002) and had lower BMI-SDS (p< 0.001) (Fig). HbA1c was lower in patients with CD (p< 0.001), even after adjustment for pump use (Fig). Across regions, gender differences in CD prevalence were not shown in Northern Europe and Asia/Middle East. HbA1c was lower in CD patients in Southern Europe and North America/Canada. In contrast, in Asia/Middle East, HbA1c was significantly higher among CD patients (p<0.001). No difference was found in Northern Europe. The frequency, anthropometric as well as metabolic consequences of CD in T1D children differs around the world.


A. Taczanowska: None. A. Schwandt: None. S. Amed: None. J. Svensson: Advisory Panel; Self; Janssen Pharmaceuticals, Inc., Medtronic. Speaker's Bureau; Self; Novo Nordisk A/S, Sanofi-Aventis. Stock/Shareholder; Self; Novo Nordisk A/S. A. Szypowska: None. C. Kanaka-Gantenbein: None. P. Toth-Heyn: None. S. Krepel Volsky: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at